The $180 area is our intermediate-term price objective.
The storied but out-of-favor name could retrace a recent rally, which could present an opportunity to buy.
There's also a report that the new vaccines appeared to maintain efficacy against new strain(s) of the virus.
The background story of PTON seems positive, but the charts are not shouting 'jump back in.'
Let's unmask what the charts say,
Consider adding or going long above this critical price level.
Investors continue to be more aggressive sellers of DXCM.
A 'careful' approach is in order for traders.
MCK is a Covid vaccine distribution play.
Let's review the charts and indicators.